Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes. But we don’t have to be.
is it so brutal to suggest caution?!??
#savesmoney
Not at all
It is wise in the stock market
But too much caution males the stock market refundant
any news on the two presentations that were to take place 16th to 21st sept ?when are they /
Imriegr, honestly? I might have to apologise to Sang R.E. "investors" after that one. Or is this a wind up ??
The 'good' news is the science, on the basis of results so far, looks great and we're fully funded through to the end of next year, if milestones are met. We've been promised key updates this quarter.
The 'bad' news is we've not had a key oncology update yet, why?? And Oliveira's selling up could drove the SP a lot lower, easily into the 50s, when there's no sign of any institution jumping in to replace him.
Agree with Sangi that if you're confident in the science, and happy to work to a 3 year timescale, this could do very well; potentially very well on a shorter timescale even.
But with every day that passes, without an update, this feels riskier and riskier to me.
I said yesterday I'd consider topping up if this hit mid 60s, on balance I think it needs to hit mid 50s before I'll top up further - but that's because my portfolio is overweight on 4D as it is.
Each to their own though.
Tick you up on that.
Short term who knows? Oliveira must have sold a large amount of his holding though. Been at it since 2nd Sep when price was much higher.
Any share can go anywhere.
RBS got to 10p. Lloyds 22p. Glencore 65p . Etc etc
But he will eventually run out of shares.
Ok the s/p coukd be anywhere. But as you say…updates are on the cards. Several irons in fire. 0518? Never count on success but has been promising to date.
It’s all up in the air atm.
Buy or forget.
I’m overweight too. Not just physically ( I’m not). In 4D. But yer pays yer money….
"Sunnyca- agree, I really cannot understand why it is that highly intelligent people who work in biotech cannot compute that times have changed and that private investors are now a very significant audience and they need to be explained things in layman's terms.
Tech sector are already doing it, all other sectors are really. Time for biotech to get off their high horse perhaps (I find this is not just a 4D thing)"
I get the frustration but I also get why, for want of a better term, they don't dumb down the language. I don’t think it’s controversial to say that the strategy of any business should be to aim its main investor communications at the profile of investor that is most important to it and its long-term success, be they current or potential investors. Like it or hate it, for small pre-commercial drug focused companies such as 4D that profile of investor is not the layman private retail investor who has limited knowledge of the space.
I might be wrong but 4d hasn't announced results since the Blautix results last October. Thats 12 months without new results. While theres been a lot of updates and positive news, without study results the SP will continue to bounce around. Particularly when it comes to institutions buying in.
Biotech is a binary game when it comes to investing, study results move the share price permanently, positive it goes up, negative it goes down. Everything else will cause ripples.
I've bought in slowly to average down and am confident in the investment, 4D have too many products in the pipeline for it to be a complete failure.
Shorts having to work a bit harder
12:14:24 66.60 2,307 Sell* 1,536 A 12:14:24 66.60 367 Sell* 244.42 A
12:14:24 66.60 1,940 Sell* 1,292 12:14:24 66.10 256 Sell* 169.22 A
12:14:24 66.20 886 Sell* 586.53 A 12:14:24 66.20 1,700 Sell* 1,125 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 2,036 Sell* 1,356 A
12:14:24 66.60 271 Sell* 180.49 A
12:14:24 66.20 4,782 Sell* 3,166 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 96 Sell* 63.94 A
12:14:24 66.60 2,211 Sell* 1,473 A
12:14:24 66.20 2,571 Sell* 1,702 A
12:14:24 66.20 2,007 Sell* 1,329 A
12:14:24 66.60 2,307 Sell* 1,536 A
12:14:25 66.00 1,677 Sell* 1,107 A
12:14:25 66.00 3,323 Sell* 2,193 A
12:14:25 66.00 2,583 Sell* 1,705 A
12:14:25 66.00 185 Sell* 122.10 A
12:14:25 66.10 1,700 Sell* 1,124 A
12:14:25 66.10 5,000 Sell* 3,305 A
12:14:25 66.00 3,732 Sell* 2,463 A
12:14:25 66.60 1,700 Sell* 1,132 A
12:14:25 66.60 1,453 Sell* 967.70 A
1. Hold nerve.
2. Be patient.
3. Have faith in your research, which is why you originally invested here (or should be).
It's only human to question yourself when you see the price drop like this and to wonder if you've done the right thing. I keep reminding myself that there are so many possibilities for this company and multiple chances to commercialise their research.
Just added again to average down a bit and just to make sure I'm not kicking myself when this takes off!
Good luck to everyone and thank you for making this a great board to visit.
Nice post RR3
Agreed.
And apart from the odd crank this is a supportive bunch yes.
I’m in Ncyt. Cat-fight!!!